PT  - JOURNAL ARTICLE
AU  - Helwick, Caroline
ED  - Konstam, Marvin A.
TI  - EVEREST: Modest Gains from Tolvaptan in Heart Failure
DP  - 2007 Jun 01
TA  - MD Conference Express
PG  - 15--16
VI  - 7
IP  - 1
4099  - http://mdc.sagepub.com/content/7/1/15.2.short
4100  - http://mdc.sagepub.com/content/7/1/15.2.full
AB  - Results from the EVEREST trial indicated that in patients with acute decompensated heart failure, tolvaptan, an oral nonpeptide vasopressin V2-receptor blocker, did not reduce mortality or hospitalizations but did provide modest symptomatic relief.